Stockscreener 앱 받기
26.34
0.50%
0.1715
전일 마감가:
$26.17
열려 있는:
$26.43
하루 거래량:
10,930
Relative Volume:
0.01
시가총액:
$3.84B
수익:
-
순이익/손실:
$-272.55M
주가수익비율:
-13.65
EPS:
-1.93
순현금흐름:
$-243.55M
1주 성능:
-6.24%
1개월 성능:
-10.45%
6개월 성능:
-13.20%
1년 성능:
-20.21%
1일 변동 폭
$26.21
$26.43
1주일 범위
$24.61
$28.04
52주 변동 폭
$24.61
$45.58
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-580-3099
주소
320 WEST 37TH STREET, NEW YORK, NY
IMVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| IMVT | 26.35 | 3.84B | 0 | -272.55M | -243.55M | -1.93 |
| VRTX | 447.65 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.99 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.27 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.49 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus - MSN
Immunovant stock hits 52-week low at $24.66 amid market shifts - Investing.com Nigeria
Principal Financial Group Inc. Purchases 391,436 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
(IMVT) Technical Data - Stock Traders Daily
FMR LLC's Strategic Acquisition of Immunovant Inc Shares - GuruFocus.com
Immunovant: Pipeline Progressing With One Minor Delay (NASDAQ:IMVT) - Seeking Alpha
Immunovant (NASDAQ:IMVT) Posts Earnings Results, Misses Expectations By $0.15 EPS - MarketBeat
Analysts Provide An Important Insights On Immunovant Inc (IMVT) - Stocks Register
Immunovant’s Strategic Advances in Autoimmune Therapies - TipRanks
Interesting IMVT Put And Call Options For March 2025 - Nasdaq
Immunovant's (IMVT) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Immunovant Inc (IMVT) Quarterly 10-Q Report - Quartzy
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 - The Manila Times
Immunovant Advances IMVT-1402 with 5 IND Clearances Despite Widening Losses | IMVT Stock News - StockTitan
Immunovant Breaks Above 200-Day Moving AverageBullish for IMVT - Nasdaq
Emerald Mutual Fund Advisers Trust Has $5.24 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Where are the Opportunities in (IMVT) - Stock Traders Daily
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Position Boosted by abrdn plc - MarketBeat
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $48.10 - MarketBeat
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - The Manila Times
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - ForexTV.com
Immunovant's chief medical officer sells $94,171 in stock By Investing.com - Investing.com Canada
Immunovant CTO Jay Stout sells $80,912 in stock By Investing.com - Investing.com Canada
Immunovant, Inc. (NASDAQ:IMVT) CTO Sells $80,912.20 in Stock - MarketBeat
Immunovant CTO Jay Stout sells $80,912 in stock - Investing.com India
Immunovant's chief medical officer sells $94,171 in stock - Investing.com India
Immunovant's chief legal officer Mark Levine sells shares worth $128,780 By Investing.com - Investing.com Australia
Immunovant's chief legal officer Mark Levine sells shares worth $128,780 - Investing.com
Immunovant CFO Eva Renee Barnett sells $94,172 in stock By Investing.com - Investing.com Australia
Immunovant's chief medical officer William Macias sells $91,782 in stock - Investing.com India
Immunovant's chief legal officer sells $82,339 in stock By Investing.com - Investing.com Australia
Immunovant's chief legal officer sells $82,339 in stock - Investing.com India
Exchange Traded Concepts LLC Buys 9,438 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant CFO Eva Renee Barnett sells $94,172 in stock - Investing.com
Immunovant CEO Peter Salzmann sells $261,845 in shares By Investing.com - Investing.com Australia
Immunovant CEO Peter Salzmann sells $261,845 in shares - Investing.com
Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $91,782.52 in Stock - MarketBeat
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
IMVT (Immunovant Inc) has impressive results - US Post News
Raymond James gives an Outperform recommendation for Immunovant Inc (IMVT) - Knox Daily
Analyzing Ratios: Immunovant Inc (IMVT)’s Financial Story Unveiled - The Dwinnex
Immunovant: Switching Lead Candidates Increases Risk (NASDAQ:IMVT) - Seeking Alpha
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immunovant Inc 주식 (IMVT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Geffner Michael | Chief Medical Officer |
Oct 23 '24 |
Sale |
29.53 |
3,189 |
94,171 |
134,971 |
| Stout Jay S | Chief Technology Officer |
Oct 23 '24 |
Sale |
29.53 |
2,740 |
80,912 |
142,186 |
| Salzmann Peter | Chief Executive Officer |
Oct 16 '24 |
Sale |
28.79 |
9,095 |
261,845 |
994,789 |
| Macias William L. | Chief Medical Officer |
Oct 16 '24 |
Sale |
28.79 |
3,188 |
91,783 |
365,144 |
| Levine Mark S. | Chief Legal Officer |
Oct 16 '24 |
Sale |
28.79 |
2,860 |
82,339 |
327,239 |
| Barnett Eva Renee | Chief Financial Officer |
Oct 16 '24 |
Sale |
28.79 |
3,271 |
94,172 |
335,343 |
| Barnett Eva Renee | Chief Financial Officer |
Oct 09 '24 |
Sale |
29.56 |
5,162 |
152,589 |
338,614 |
| Salzmann Peter | Chief Executive Officer |
Oct 09 '24 |
Sale |
29.56 |
4,460 |
131,838 |
1,003,884 |
| Levine Mark S. | Chief Legal Officer |
Aug 21 '24 |
Sale |
31.86 |
3,295 |
104,976 |
330,099 |
| Macias William L. | Chief Medical Officer |
Aug 21 '24 |
Sale |
31.86 |
3,027 |
96,437 |
368,332 |
0.42%
0.16%
자본화:
|
볼륨(24시간):